This case provides critical early insight into the potential role of dual PD-1 and VEGFA blockade in overcoming resistance in molecularly complex NSCLC with MPE and underscores the need for further investigation into biomarker-driven treatment strategies for this challenging patient population. Here, VEGFA is linked to non-small cell lung carcinoma.